Sign up to save your podcasts
Or
Share Adam Brufsky, MD, PhD - Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Adam Brufsky, MD, PhD - Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice
Go online to PeerView.com/JTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evidence on this therapeutic class that helps inform clinical practice. Upon completion of this activity, participants should be better able to: Discuss real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in metastatic breast cancer, Establish best practices for analyzing and interpreting real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday oncology practice, Implement appropriate clinical decisions regarding the selection and use of CDK 4/6 inhibitors in the treatment of patients with metastatic breast cancer informed by the latest real-world and clinical trial evidence.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/JTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evidence on this therapeutic class that helps inform clinical practice. Upon completion of this activity, participants should be better able to: Discuss real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in metastatic breast cancer, Establish best practices for analyzing and interpreting real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday oncology practice, Implement appropriate clinical decisions regarding the selection and use of CDK 4/6 inhibitors in the treatment of patients with metastatic breast cancer informed by the latest real-world and clinical trial evidence.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
317 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
115 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
486 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
10 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners